Unlocking the therapeutic potential of Fc-Receptors in autoimmune diseases

SuppreMol GmbH is a private biotechnology company located in Martinsried near Munich, Germany, and is focused on the development of novel therapeutics for the treatment of autoimmune diseases. In particular the Company is focused on the development of soluble Fcγ-Receptors (sFcRs) which are recombinant autologous therapeutic proteins endowed with a proven strong immunosuppressive potential. SuppreMol will develop sFcR as a therapeutic for autoimmune diseases such as Idiopathic Thrombocytopenic Purpura in the first instance and then Systemic Lupus Erythematosus, and Rheumatoid Arthritis. The Company promotes an additional program to develop an anti-FcγRIIb monoclonal antibody to target FcγR receptors. The Company was founded in 2002 as a spin-off from the Max-Planck-Institute of Biochemistry in Martinsried/Germany.